Last week two companies reported news on their clinical trials for myeloproliferative neoplasms:
- AOP Orphan Pharmaceuticals announced that Phase III trials were going well for their study on Pegasys in PV patients. This study is being conducted in Europe and is currently recruiting.
- Promedior has initiated a new Phase II clinical trial for their compound, PRM-151, in people with myelofibrosis.
Ongoing clinical trials for PV, ET, and MF can be found at clinicaltrials.gov as well as the MPN Research Foundation’s site. Participating in a clinical trial should be considered carefully and discussed with your physician and family.